Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New pill aims to keep ulcerative colitis in check for a year

NCT ID NCT07459686

Not yet recruiting Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Mar 10, 2026 · Last updated May 01, 2026 · Updated 5 times

Summary

This study looks at the safety and effectiveness of the drug Velsipity (2 mg tablets) when used for up to 52 weeks in people with moderate to severe ulcerative colitis. About 553 participants will take the medicine as part of their normal care. Researchers will track serious infections and other side effects, as well as how many people achieve symptom relief.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.